• Journal of KIISE:Computing Practices and Letters
• /
• v.16 no.6
• /
• pp.712-716
• /
• 2010

In this paper, we propose a novel shape-based approach to detect CNV regions (CNVR) by analyzing the coverage graph obtained by aligning the giga-sequencing data onto the human reference sequence. The proposed algorithm proceeds in two steps: a filtering step and a post-processing step. In the filtering step, it takes several shape parameters as input and extracts candidate CNVRs having various depth and width. In the post-processing step, it revises the candidate regions to make up for errors potentially included in the reference sequence and giga-sequencing data, and filters out regions with high ratio of GC-contents, and returns the final result set from those candidate CNVRs. To verify the superiority of our approach, we performed extensive experiments using giga-sequencing data publicly opened by "1000 genome project" and verified the accuracy by comparing our results with those registered in DGV database. The result revealed that our approach successfully finds the CNVR having various shapes (gains or losses) in HLA (Human Leukocyte Antigen) region.

• Parasites, Hosts and Diseases
• /
• v.47 no.2
• /
• pp.83-91
• /
• 2009

The completion of many malaria parasite genomes provides great opportunities for genomewide characterization of gene expression and high-throughput genotyping. Substantial progress in malaria genomics and genotyping has been made recently, particularly the development of various microarray platforms for large-scale characterization of the Plasmodium falciparum genome. Microarray has been used for gene expression analysis, detection of single nucleotide polymorphism (SNP) and copy number variation (CNV), characterization of chromatin modifications, and other applications. Here we discuss some recent advances in genetic mapping and genomic studies of malaria parasites, focusing on the use of high-throughput arrays for the detection of SNP and CNV in the P. falciparum genome. Strategies for genetic mapping of malaria traits are also discussed.

• Journal of Korea Multimedia Society
• /
• v.12 no.8
• /
• pp.1073-1081
• /
• 2009

In this paper, we proposed new method to enhance choroidal vessels by suppressing retina vessels brightness. It is well-known that CNV(choroidal neovascularization) is related with sight loss. The main feature of CNV is the occurrence of new vessels in choroid. Unfortunately, because retina vessels brightness is stronger than choroidal vessels brightness in ICGA(indocynanine green angiography) image, so that the choroidal vessels were hardly recognized. Therefore, for correct diagnosis, the choroidal vessels must be enhanced in ICGA image. The proposed enhancement method consists of 3 strategies. First, the retina vessels were detected by multi scale enhancement technique, hysteresis thresholding, KNN(Kth-nearest neighbor) classification method. And then, a retina vessel mask was generated from detection result. Next, the brightness of retina vessels was suppressed by the proposed conditional region erosion method and mask region until the mask region was vanished. Finally, the brightness of choroidal vessel was enhanced on processed image. Through an experiment, we had confirmed that the proposed method was robust and efficient.

• Journal of Animal Science and Technology
• /
• v.49 no.5
• /
• pp.559-568
• /
• 2007

Recently, copy number variations (CNV) of genes or genomic segments have been intensively studied and various analysis methods have been developed. In this study, quantitative oligonucleotide ligation assay (qOLA) was applied to investigate CNV of KIT gene in the Landrace breed. A combined assay using qOLA and pyrosequencing, 6 genotype classes, I1/I1 or I3/i (IBe), I1/I2 or I3/IP, I1/I3, I1/IP or I2/i (IBe), I2/I2and I2/IP, were identified from 44 Landrace pigs. Genotype assignment using grouping features of measurements on a scatter plot showed 100% agreement with those using a statistical assignment by PROC FASTCLUS procedure implemented in the SAS package. Two versions (3100 and 3130) of ABI sequencers gave the same genotyping results, indicating there was no influence on qOLA by different versions of instrument, however, the means of standard deviation and coefficient of variation from the qOLA on a ABI 3130 (2.33 and 4.10) was lower than those from the qOLA on a ABI 3100 (2.67 and 4.81). Effect of proteinase K treatment on the PCR product followed by qOLA was very clear because noise peaks were disappeared and the observed ration fit better to the reference ratio corresponding to each genotype.

• Journal of Genetic Medicine
• /
• v.18 no.1
• /
• pp.31-37
• /
• 2021

Purpose: To summarize the results of chromosomal microarray analysis (CMA) for copy number variants (CNVs) detection and clinical utility in a single tertiary hospital. Materials and Methods: We performed CMA in 46 patients over the course of two years. Detected CNVs were classified into five categories according to the American College of Medical Genetics and Genomics guidelines and correlated with clinical manifestations. Results: A total of 31 CNVs were detected in 19 patients, with a median CNV number per patient of two CNVs. Among these, 16 CNVs were classified as pathogenic (n=3) or likely pathogenic (LP) (n=11) or variant of uncertain significance (n=4). The 16p11.2 deletion and 16p13.11 deletion classified as LP were most often detected in 6.5% (3/46), retrospectively. CMA diagnostic yield was 24.3% (9/37 patients) for symptomatic patients. The CNVs results of the commercial newborn screening test using next generation sequencing platforms showed high concordance with CMA results. Conclusion: CMA seems useful as a first-tier test for developmental delay with or without congenital anomalies. However, the classification and interpretation of CMA still remained a challenge. Further research is needed for evidence-based interpretation.

• Korean Journal of Clinical Laboratory Science
• /
• v.55 no.1
• /
• pp.16-28
• /
• 2023

Lung adenocarcinoma accounts for about 40% of all lung cancers. With the recent development of gene profiling technology, studies on mutations in oncogenes and tumor suppressor genes, which are important for the development and growth of tumors, have been actively conducted. Companion diagnosis using next-generation sequencing helps improve survival with targeted therapy. In this study, formalin-fixed paraffin-embedded tissues of non-small cell lung cancer patients were subjected to hematoxylin and eosin staining for detecting genetic mutations that induce lung adenocarcinoma in Koreans. Immunohistochemical staining was also performed to accurately classify lung adenocarcinoma tissues. Based on the results, next-generation sequencing was applied to analyze the types and patterns of genetic mutations, and the association with smoking was established as the most representative cause of lung cancer. Results of next-generation sequencing analysis confirmed the single nucleotide variations, copy number variations, and gene rearrangements. In order to validate the reliability of next-generation sequencing, we additionally performed the existing genetic testing methods (polymerase chain reaction-epidermal growth factor receptor, immunohistochemistry-anaplastic lymphoma kinase (D5F3), and fluorescence in situ hybridiation-receptor tyrosine kinase 1 tests) to confirm the concordance rates with the next-generation sequencing test results. This study demonstrates that next-generation sequencing of lung adenocarcinoma patients simultaneously identifies mutation.

• Journal of Genetic Medicine
• /
• v.7 no.2
• /
• pp.111-118
• /
• 2010

Chromosomal microarray analysis (CMA) enables the genome-wide detection of submicroscopic chromosomal imbalances with greater precision and accuracy. In most other countries, CMA is now a commonly used clinical diagnostic test, replacing conventional cytogenetics or targeted detection such as FISH or PCR-based methods. Recently, some consensus statements have proposed utilization of CMA as a first-line test in patients with multiple congenital anomalies not specific to a well-delineated genetic syndrome, developmental delay/intellectual disability, or autism spectrum disorders. CMA can be used as an adjunct to conventional cytogenetics to identify chromosomal abnormalities observed in G-banding analysis in constitutional or acquired cases, leading to a more accurate and comprehensive assessment of chromosomal aberrations. Although CMA has distinct advantages, there are several limitations, including its inability to detect balanced chromosomal rearrangements and low-level mosaicism, its interpretation of copy number variants of uncertain clinical significance, and significantly higher costs. For these reasons, CMA is not currently a replacement for conventional cytogenetics in prenatal diagnosis. In clinical applications of CMA, knowledge and experience based on genetics and cytogenetics are required for data analysis and interpretation, and appropriate follow-up with genetic counseling is recommended.